Radioiodine-refractory Differentiated Thyroid Cancer
📧 Sign up to get email alerts when something new happens for Radioiodine-refractory Differentiated Thyroid Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer [Phase 2]
This update describes a Phase 2 trial evaluating encorafenib and binimetinib, with or without nivolumab, for metastatic radioiodine-refracto…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer [NA]
A clinical trial update indicates recruitment for a study of Sacituzumab Govitecan in combination with immunotherapy for advanced thyroid ca…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer [EARLY_Phase 1]
Early-phase clinical trial evaluating 177Lu-LNC1004 injection for FAP-positive, radioiodine-refractory differentiated thyroid cancer, curren…
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 [NA]
A Memorial Sloan Kettering trial evaluated whether pretreatment with the MEK inhibitor selumetinib (AZD6244) can restore radioactive iodine …